Symbol="XTLB"
AssetType="Common Stock"
Name="XTL Biopharmaceuticals Ltd ADR"
Description="XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company is headquartered in Ramat Gan, Israel."
CIK="1023549"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="XTL BIOPHARMACEUTICALS LTD, C/O ALSTON & BIRD LLP, 90 PARK AVENUE, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="4958600"
EBITDA="-842000"
PERatio="None"
PEGRatio="0"
BookValue="0.5"
DividendPerShare="0"
DividendYield="0"
EPS="-0.47"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.122"
ReturnOnEquityTTM="-0.689"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.47"
QuarterlyEarningsGrowthYOY="-0.76"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="30"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.459"
EVToRevenue="-"
EVToEBITDA="-2.578"
Beta="0.863"
num_52WeekHigh="1.6"
num_52WeekLow="0.75"
num_50DayMovingAverage="0.977"
num_200DayMovingAverage="1.205"
SharesOutstanding="5449100"
DividendDate="2017-02-10"
ExDividendDate="None"
symbol="XTLB"
open="0.81"
high="0.89"
low="0.76"
price="0.87"
volume="1762.00"
latest_trading_day="2023-08-24"
previous_close="0.92"
change="-0.05"
change_percent="-5.4142%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="93"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="7"
Volume_recent_avg="12607"
Change_recent_avg="0.01"
Delta_recent_avg="0.07"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="1.01"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="7"
Aroon_momentum_negative="93"
image_negative_thumbnail_id_1="1164"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0198.jpeg"
image_negative_thumbnail_id_2="98"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0078.jpeg"
image_neutral_thumbnail_id_1="567"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0032.jpeg"
image_neutral_thumbnail_id_2="532"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0067.jpeg"
image_positive_thumbnail_id_1="986"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0148.jpeg"
image_positive_thumbnail_id_2="989"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0151.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1191"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0025.jpeg"
